Insights on Ingrezza Usage Interactions and Safety

Ingrezza contains valbenazine and is taken orally. Its use depends on the condition being treated and the individual treatment plan. The FDA prescribing information identifies specific interactions and precautions that should be considered before and during treatment.

Ingrezza Usage and Important Interactions

Ingrezza can interact with medicines that influence how valbenazine is metabolized. These interactions may change the amount of medicine in the body and can affect either safety or treatment effectiveness. Healthcare professionals may need to adjust the Ingrezza dose or avoid particular combinations depending on the medicines being taken.

Important interaction considerations include:

• MAO inhibitors: Concomitant use should be avoided, including within 14 days after stopping an MAOI.
• Strong CYP3A4 inhibitors: These can increase exposure to valbenazine, and the recommended dose is reduced when they are used together.
• Strong CYP2D6 inhibitors: These can increase exposure to the active metabolite, with dose reduction recommended.
• Strong CYP3A4 inducers: These can decrease exposure and potentially reduce treatment effectiveness, so concomitant use is not recommended.
• Patients should provide healthcare professionals with a complete list of prescription medicines, over the counter medicines, and supplements.

Ingrezza Safety Considerations and Monitoring

Safety considerations vary according to the individual's medical history and the reason Ingrezza is prescribed. The current FDA labeling includes warnings concerning depression and suicidal thoughts or behavior in patients with Huntington’s disease. It also warns about QT interval prolongation, neuroleptic malignant syndrome, and parkinsonism.

Key safety considerations include:

• Sleepiness: Somnolence is among the commonly reported adverse reactions and may affect activities requiring alertness.
• Heart rhythm: Ingrezza may increase the QT interval, so particular caution is needed in people with certain heart rhythm conditions.
• Parkinsonism: Parkinson-like symptoms have been reported, and clinically significant symptoms may require dose reduction or discontinuation.
• Neuroleptic malignant syndrome: This is a serious reaction requiring prompt medical attention and discontinuation if it occurs.
• Pregnancy and breastfeeding: The FDA labeling states that Ingrezza may cause fetal harm and advises against breastfeeding during treatment.

Ingrezza should be used according to the prescribing information and the instructions of a qualified healthcare professional. Medication interactions and individual risk factors can change over time, so treatment decisions should be based on an up-to-date medication and medical history review.

Understanding Ingrezza usage, interactions, and safety considerations is important for appropriate treatment planning. Valbenazine can interact with several types of medicines, particularly those affecting CYP3A4 and CYP2D6, while certain combinations should be avoided. Monitoring for adverse effects and discussing existing medical conditions and medications with a healthcare professional can help support safer use. This information is educational only and is not intended to provide medical advice, diagnosis, treatment, sales, or services.